The metabolism of methaqualone in patients with biliary cirrhosis or secondary carcinoma of the liver.
The metabolism of methaqualone has been studied in three patients with secondary carcinoma of the liver and two with biliary cirrhosis. The urinary excretion of five C-monohydroxy metabolites and the N-oxide was studies in the 24 h period immediately after oral dosing with 250 mg methaqualone (Melsed). In both patients with biliary cirrhosis and one with primary carcinoma of the bile duct or pancreas with secondaries in the liver the pattern of metabolites was normal. In a patient with oat cell carcinoma with secondaries in the liver some metabolite patterns were disturbed and increased metabolite excretion occurred. A patient with primary carcinoma of the breast with secondaries in the liver gave a completely abnormal metabolite pattern.
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D006900:Hydroxylation; D008105:Liver Cirrhosis, Biliary / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism*; D008297:Male; D008702:Methaqualone / Q000378:metabolism* / Q000652:urine; D008875:Middle Aged; D010084:Oxidation-Reduction
D008702:Methaqualone